A phase III trial of nab-paclitaxel versus dacarbazine in chemotherapy-naive patients with metastatic melanoma: A subanalysis based on BRAF status

Evan Hersh; Michele Del Vecchio; Michael Paul Brown; Richard Kefford; Carmen Loquai; Alessandro Testori; Caroline Robert; Mingyu Li; Ileana Elias; Markus F. Renschler; Axel Hauschild

doi:10.1200/jco.2013.31.15_suppl.9030

A phase III trial of nab-paclitaxel versus dacarbazine in chemotherapy-naive patients with metastatic melanoma

A subanalysis based on BRAF status

Evan Hersh, Michele Del Vecchio, Michael Paul Brown, Richard Kefford, Carmen Loquai, Alessandro Testori, Caroline Robert, Mingyu Li, Ileana Elias, Markus F. Renschler, Axel Hauschild

Research output: Contribution to journal › Meeting abstract

Original language	English
Pages (from-to)	9030-9030
Number of pages	1
Journal	Journal of Clinical Oncology
Volume	31
Issue number	15 supplement
DOIs	https://doi.org/10.1200/jco.2013.31.15_suppl.9030
Publication status	Published - 20 May 2013
Event	Annual Meeting of the American Society of Clinical Oncology (ASCO) - Chicago, United States Duration: 31 May 2013 → 4 Jun 2013

Cite this

Hersh, E., Del Vecchio, M., Brown, M. P., Kefford, R., Loquai, C., Testori, A., ... Hauschild, A. (2013). A phase III trial of nab-paclitaxel versus dacarbazine in chemotherapy-naive patients with metastatic melanoma: A subanalysis based on BRAF status. Journal of Clinical Oncology, 31(15 supplement), 9030-9030. https://doi.org/10.1200/jco.2013.31.15_suppl.9030

Hersh, Evan ; Del Vecchio, Michele ; Brown, Michael Paul ; Kefford, Richard ; Loquai, Carmen ; Testori, Alessandro ; Robert, Caroline ; Li, Mingyu ; Elias, Ileana ; Renschler, Markus F. ; Hauschild, Axel. / A phase III trial of nab-paclitaxel versus dacarbazine in chemotherapy-naive patients with metastatic melanoma : A subanalysis based on BRAF status. In: Journal of Clinical Oncology. 2013 ; Vol. 31, No. 15 supplement. pp. 9030-9030.

@article{b161832300384fb0894bfd5458317acb,

title = "A phase III trial of nab-paclitaxel versus dacarbazine in chemotherapy-naive patients with metastatic melanoma: A subanalysis based on BRAF status",

author = "Evan Hersh and {Del Vecchio}, Michele and Brown, {Michael Paul} and Richard Kefford and Carmen Loquai and Alessandro Testori and Caroline Robert and Mingyu Li and Ileana Elias and Renschler, {Markus F.} and Axel Hauschild",

year = "2013",

month = "5",

day = "20",

doi = "10.1200/jco.2013.31.15_suppl.9030",

language = "English",

volume = "31",

pages = "9030--9030",

journal = "Journal of Clinical Oncology",

issn = "1527-7755",

publisher = "American Society of Clinical Oncology",

number = "15 supplement",

}

Hersh, E, Del Vecchio, M, Brown, MP, Kefford, R, Loquai, C, Testori, A, Robert, C, Li, M, Elias, I, Renschler, MF & Hauschild, A 2013, 'A phase III trial of nab-paclitaxel versus dacarbazine in chemotherapy-naive patients with metastatic melanoma: A subanalysis based on BRAF status', Journal of Clinical Oncology, vol. 31, no. 15 supplement, pp. 9030-9030. https://doi.org/10.1200/jco.2013.31.15_suppl.9030

A phase III trial of nab-paclitaxel versus dacarbazine in chemotherapy-naive patients with metastatic melanoma : A subanalysis based on BRAF status. / Hersh, Evan; Del Vecchio, Michele; Brown, Michael Paul; Kefford, Richard; Loquai, Carmen; Testori, Alessandro; Robert, Caroline; Li, Mingyu; Elias, Ileana; Renschler, Markus F.; Hauschild, Axel.

In: Journal of Clinical Oncology, Vol. 31, No. 15 supplement, 20.05.2013, p. 9030-9030.

Research output: Contribution to journal › Meeting abstract

TY - JOUR

T1 - A phase III trial of nab-paclitaxel versus dacarbazine in chemotherapy-naive patients with metastatic melanoma

T2 - A subanalysis based on BRAF status

AU - Hersh, Evan

AU - Del Vecchio, Michele

AU - Brown, Michael Paul

AU - Kefford, Richard

AU - Loquai, Carmen

AU - Testori, Alessandro

AU - Robert, Caroline

AU - Li, Mingyu

AU - Elias, Ileana

AU - Renschler, Markus F.

AU - Hauschild, Axel

PY - 2013/5/20

Y1 - 2013/5/20

U2 - 10.1200/jco.2013.31.15_suppl.9030

DO - 10.1200/jco.2013.31.15_suppl.9030

M3 - Meeting abstract

VL - 31

SP - 9030

EP - 9030

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 1527-7755

IS - 15 supplement

ER -

Access to Document

10.1200/jco.2013.31.15_suppl.9030